RESTANCE Highlights #DoItForAfrica Campaign Anticipated to Generate $20 Million in Annual Sales

Friday, October 27, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

SPARKS, Nevada, October 27, 2017 /PRNewswire/ --

RESTANCE, Inc. (USOTC: ANCE) today announced publishing highlights

on the company's website for the upcoming buy-one-give-one #DoItForAfrica campaign anticipated to generate $20 million in annual sales and contribute to the United Nations goal of eliminating the spread of AIDS in
Africa. RESTANCE has acquired the tools to equip a condom manufacturing plant and plans to open a condom manufacturing plant in Kenya soon to produce condoms for all Africa.

RESTANCE is pursuing several business lines in the growing economies of East Africa. The Company is developing opportunities in the region including initiatives in technology and systems integration services, utility support services, affordable housing and health products manufacturing. RESTANCE recently acquired East African Development Partners as part of its strategy in East Africa.

Learn more about the RESTANCE operations in Africa on the Company's website:

http://www.restanceinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Randell Torno [email protected] +1-800-834-5792

SOURCE RESTANCE, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store